Tokyo, July 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061966) titled 'Real-world effectiveness of existing therapies in patients with pancreatic cancer in Japan using genomic data' on June 30.
Study Type:
Observational
Primary Sponsor:
Institute - Eli Lilly Japan K.K.
Condition:
Condition - Advanced/metastatic pancreatic ductal adenocarcinoma (PDAC)
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - To evaluate the effectiveness of existing therapies using objective response rate (ORR) in a C-CAT cohort adjusted to match baseline characteristics of the JZQA trial cohort.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
=18 years
Key exclusion criteria - - Multiple primary cancers
- Missing key variables required for adjustment
- No tumor response assessment after second-line treatment
Target Size - 100
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 02 Month 13 Day
Date of IRB - 2026 Year 03 Month 05 Day
Anticipated trial start date - 2026 Year 03 Month 09 Day
Last follow-up date - 2027 Year 01 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070908
Disclaimer: Curated by HT Syndication.
